Organization
Zhejiang Cancer Hospital, Chinese Academy of Sciences
28 abstracts
Abstract
Association of homologous recombination repair mutation defined with a 15-gene panel with the prognosis of epithelial ovarian cancer: A Chinese multicenter retrospective study.Org: The Affiliated Zhongda Hospital, Southeast University, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Department of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Department of Obstetrics and Gynaecology, Zhongda Hospital, School of Medicine, Southeast University,
Abstract
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study.Org: Fujian Cancer Hospital, First Chest Radiotherapy Department, Hunan Cancer Hospital, Changsha, China, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, Department of Melanoma Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China, The Third People's Hospital of Zhengzhou,
Abstract
The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Lishui Central Hospital, Akeso Biopharma, Inc., Zhongshan, China,
Abstract
The efficacy and safety of donafenib combined with transcatheter arterial chemoembolization and anti-PD-1 antibodies as first-line therapy for hepatocellular carcinoma: A retrospective study.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Department of Interventional Radiology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
A phase Ia/b trial of ARX788 combined with toripalimab for HER2-low advanced breast cancer (ABC) and other HER2-expressing solid tumors.Org: Department of Breast Medical Oncology, Fujian Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Center of Hepato-Pancreato-Biliary Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, First Affiliated Hospital of Wannan Medical College, Sun Yat-sen University Cancer Center Gansu Hospital,
Abstract
Real-world effectiveness and safety of PD-1 inhibitors combined with recombinant human endostatin and chemotherapy in refractory, recurrent/metastatic nasopharyngeal carcinoma.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou Yirui Pharmaceutical Technology,
Abstract
Neoadjuvant chemoradiotherapy (nCRT) combined with sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): Preliminary results of a single-arm, open-label phase Ib trial (CRIS).Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou Yirui Pharmaceutical Technology, China National Biotec Group, Zhejing Cancer Hospital,
Abstract
Induction chemotherapy with nab-paclitaxel plus nedaplatin plus concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A retrospective real-world study.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou Yirui Pharmaceutical Technology, Zhejiang ACEA Pharmaceutical, China National Biotec Group,
Abstract
IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: A phase I dose-escalation study.Org: Fudan University Shanghai Cancer Center, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Shandong Provincial Institute of Cancer Prevention and Treatment, The First Affiliated Hospital of Henan University of Science and Technology, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai, China,
Abstract
Phase I clinical study of FC084CSA, a high selective AXL kinase inhibitor that ameliorates tumor microenvironment and augments the effectivity of immunotherapy.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Shanghai Pulmonary Hospital, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai Henlius Biotech,
Abstract
Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial.Org: Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Liaoning Cancer Hospital and Institute, Shenyang, China,
Abstract
Safety and efficacy of QL1706 plus carboplatin/etoposide (EC) as first-line (1L) treatment for extensive-stage small-cell lung cancer (ES-SCLC): The results from a phase II single-arm study.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Yunnan Cancer Hospital, Kunming, Yunnan, China, Anhui Chest Hospital,
Abstract
FAK inhibition with novel FAK/ALK inhibitor APG-2449 could overcome resistance in NSCLC patients who are resistant to second-generation ALK inhibitors.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Hunan Provincial Oncology Hospital, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Respiratory Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
IMM01 plus tislelizumab in patients with advanced solid tumors and lymphoma: An open-label, multicenter, phase 1b/2 dose escalation and expansion study (IMM01-04).Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, The Third Affiliated Hospital Of Qiqihar Medical University, Shandong Provincial Institute of Cancer Prevention and Treatment, Henan Cancer Hospital, Shanghai Lung Cancer Center,
Abstract
Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.Org: Peking University Cancer Hospital & Institute, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, The Third People's Hospital of Zhengzhou, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China,
Abstract
A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors.Org: BeiGene USA, Inc., San Mateo, CA, BeiGene (Shanghai) Co., Ltd., UPMC Hillman Cancer Center, Auckland Cancer Trials Centre Governance Group, Harbour Cancer & Wellness,
Abstract
A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.Org: Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Chinese Academy of Sciences,
Abstract
Adjuvant nab-paclitaxel plus S-1 versus capecitabine plus oxaliplatin for patients with stage III gastric adenocarcinoma after D2 dissection: A multicenter, open-label, randomized phase 3 study.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, University of Chinese Academy of Sciences Cancer Hospital, Hepato-Pancreato-Biliary & Gastric Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences,
Abstract
Preliminary results of a phase I dose escalation study of IMM2510, a PD-L1 and VEGF bispecific fusion protein, in patients with advanced tumors.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Fudan University Shanghai Cancer Center, Shandong Provincial Institute of Cancer Prevention and Treatment, The First Affiliated Hospital of Henan University of Science and Technology, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai, China,
Abstract
Efficacy and safety of IBI110 in combination with sintilimab and lenvatinib in first-line of advanced hepatocellular carcinoma: Preliminary results from a phase Ib study.Org: Peking University Cancer Hospital & Institute, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Union Hospital Tongji Medical College Huazhong University of Science and Technology, The First Hospital with Nanjing Medical University Jiangsu Province Hospital,
Abstract
Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin.Org: Fudan University Shanghai Cancer Center, Cancer Institute of Jiangsu Province, Shanghai Medical College, Fudan University, The Fourth Hospital of Hebei Medical University, The First Hospital of Jilin University, Changchun, Jilin Province, China,
Abstract
Real-world data from a multi-center study: Insights to the efficacy and safety in patients with ovarian cancer (OC) received niraparib as first-line (1st-L) maintenance therapy (MT).Org: Zhongda Hospital, Southeast University, School of Medicine, Zhejiang University, Hangzhou, China, University of Science and Technology of China, Fudan University (Xiamen Branch), Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research,
Abstract
Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).Org: Shanghai East Hospital, Tongji University, Shanghai, China, Union Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Zhejiang Cancer Hospital, Chinese Academy of Sciences, West China Hospital, Sichuan University,
Abstract
HH2853, an EZH1/2 inhibitor, in patients with epithelioid sarcoma: Preliminary results from the phase 1 part of a first-in-human phase I/II study.Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Sun Yat-sen University Cancer Center Gansu Hospital, Department of Rare Cancer & Head and Neck Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Zhejiang Cancer Hospital, Chinese Academy of Sciences,
Abstract
Real world study on the effect of PARPi as maintenance therapy after first-line and second-line chemotherapy on platinum sensitivity in patients with recurrent high-grade serous epithelial ovarian cancer.Org: Zhejiang Cancer Hospital (China), Zhejiang Cancer Hospital, Chinese Academy of Sciences,
Abstract
A study of antibody conjugates for the treatment of inflammatory breast cancer.Org: College of Pharmaceutical Science and Technology, Zhejiang University of Technology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Zhejiang Cancer Hospital, Chinese Academy of Sciences,
Abstract
A phase IV study to evaluate the safety of fruquintinib in Chinese real-world clinical practice.Org: Tongji University Shanghai East Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Zhejiang Cancer Hospital, Chinese Academy of Sciences,
Abstract
Phase I/II study to evaluate penpulimab combined with anlotinib and epirubicin in the first-line treatment of soft tissue sarcoma: Updated.Org: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai Henlius Biotech, China National Biotec Group,